Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NuVue Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

A game-changing, silver-bullet approach for diagnosing and treating soft-tissue cancers could replace traditional biopsy techniques and IV chemotherapy. Or so hopes NuVue Therapeutics Inc., which is developing a suite of products that could allow more precise tissue removal through an ultrasound-guided needle with color monitoring for easy visibility, plus reduce the current high rates of toxicity and morbidity associated with chemotherapy. The company says its technology enables very low-volume/highly concentrated dosing, just 1/200th to 1/500th of the standard dose of systemic chemotherapy.

You may also be interested in...



Start-Up Previews (12/2010)

A preview of the emerging health ncompanies profiled in the current issue of Start-Up. This month's profile group, "Noninvasive Body Contouring Begins To Take Shape," features profiles of EndyMed, Slender Medical and Zeltiq. Plus these Start-Ups Across Health Care: Auxogyn, Mucosis, NuVue Therapeutics, Taiga Biotechnologies and ZetrOZ.

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1135009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel